Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program

Journal of Addiction Medicine

Volumn 9, Issue 6, 2015, Pages 470-477

  Gordon, Adam J ^a,b,c   Lo Ciganic, Wei Hsuan ^c,e   Cochran, Gerald ^b,c   Gellad, Walid F ^a,b,c   Cathers, Terri ^f   Kelley, David ^f   Donohue, Julie M ^c,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f Pennsylvania Department of Human Services   (United States)

Author keywords

buprenorphine; health services; Medicaid; opioid substitution treatment; opioid related disorders

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; NALOXONE; PRESCRIPTION DRUG; NARCOTIC ANALGESIC AGENT;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DRUG USE; FEMALE; GENDER; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MIDDLE AGED; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; OUTPATIENT CARE; PATIENT CARE; PATIENT COUNSELING; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RACE; TREATMENT DURATION; UNITED STATES; URINALYSIS; YOUNG ADULT; ADOLESCENT; OPIOID-RELATED DISORDERS; STANDARDS; STATISTICAL MODEL;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MEDICAID; MIDDLE AGED; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUGS; QUALITY OF HEALTH CARE; UNITED STATES; YOUNG ADULT;

EID: 84947914126     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0000000000000164     Document Type: Article

References (39)

1. Adelmann PK. Mental and substance use disorders among medicaid recipients: prevalence estimates from two national surveys. Adm Policy Ment Health 2003;31:111-129.
2. Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 2009;104:982-992.
3. Baxter JD, Clark RE, Samnaliev M, et al. Factors associated with medicaid patients' access to buprenorphine treatment. J Subst Abuse Treat 2011;41:88-96.
4. Baxter JD, Clark RE, Samnaliev M, et al. Adherence to buprenorphine treatment guidelines in a medicaid program. Subst Abus 2015;36: 174-182.
5. Bretteville-Jensen AL, Lillehagen M, Gjersing L, Andreas JB. Illicit use of opioid substitution drugs: Prevalence, user characteristics, and the association with non-fatal overdoses. Drug Alcohol Depend 2015; 147:89-96.
6. Brooner RK, King VL, Kidorf M, et al. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 1997;54:71-80.
7. Brown H, Prescott R. Applied mixed models in medicine. England: Wiley; 2006.
8. Center for Substance Abuse Treatment. Treatment improvement protocol 40: clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville, MD; 2004.
9. Clark RE, Baxter JD. Responses of state medicaid programs to buprenorphine diversion: Doing more harm than good? J Am Med Assoc Intern Med 2013;173:1571-1572.
10. Clark RE, Baxter JD, Barton BA, et al. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for massachusetts medicaid beneficiaries with opioid dependence. Health Serv Res 2014;49:1964-1979.
11. Clark RE, Samnaliev M, Baxter JD, Leung GY. The evidence doesn't justify steps by state medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff (Millwood) 2011;30:1425-1433.
12. Ducharme LJ, Abraham AJ. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy 2008;3:17.
13. Farmer CM, Lindsay D, Williams J, et al. Practice guidance for buprenorphine for the treatment of opioid use disorders: Results of an expert panel process. Subst Abus 2015;36:209-216.
14. Fiellin DA, Barry DT, Sullivan LE, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med 2013;126:74 e11-7.
15. Fiellin DA, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med 2002;347:817-823.
16. Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenor-phine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006;355:365-374.
17. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003;349:949-958.
18. Gordon AJ, Trafton JA, Saxon AJ, et al. Implementation of buprenorphine in the veterans health administration: results of the first 3 years. Drug Alcohol Depend 2007;90:292-296.
19. Jones ES, Moore BA, Sindelar JL, et al. Cost analysis of clinic and office-based treatment of opioid dependence: Results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend 2009;99:132-140.
20. Kidorf M, Disney ER, King VL, et al. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug Alcohol Depend 2004;74:115-122.
21. Lavonas EJ, Banner W, Bradt P, et al. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children. J Pediatr 2013;163:1377-83 e1-3.
22. Lavonas EJ, Severtson SG, Martinez EM, et al. Abuse and diversion of buprenorphine sublingual tablets and film. J Subst Abuse Treat 2014;47:27-34.
23. Manlandro Jr. Buprenorphine for office-based treatment of patients with opioid addiction. J Am Osteopath Assoc 2005;105:S8-13.
24. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014;2:CD002207.
25. National Center for Health Statistics. Health, United States, 2012: with special feature on emergency care. 2013. Available at: www.cdc.gov/nchs/data/hus/hus12.pdf. Accessed April 1, 2015.
26. Oliva EM, Harris AH, Trafton JA, Gordon AJ. Receipt of opioid agonist treatment in the veterans health administration: Facility and patient factors. Drug Alcohol Depend 2012;122:241-246.
27. Oliva EM, Trafton JA, Harris AH, Gordon AJ. Trends in opioid agonist therapy in the veterans health administration: Is supply keeping up with demand? Am J Drug Alcohol Abuse 2013;39:103-107.
28. Rosen K, Gutierrez A, Haller D, Potter JS. Sublingual buprenorphine for chronic pain: a survey of clinician prescribing practices. Clin J Pain 2014;30:295-300.
29. Rosenblatt RA, Andrilla CH, Catlin M, Larson EH. Geographic and specialty distribution of us physicians trained to treat opioid use disorder. Ann Fam Med 2015;13:23-26.
30. Soyka M. Buprenorphine-naloxone buccal soluble film for the treatment of opioid dependence: Current update. Expert Opin Drug Deliv 2015;12:339-347.
31. Stein BD, Gordon AJ, Sorbero M, et al. The impact of buprenorphine on treatment of opioid dependence in a medicaid population: Recent service utilization trends in the use of buprenorphine and methadone. Drug Alcohol Depend 2012;123:72-78.
32. Stein BD, Gordon AJ, Dick AW, et al. Supply of buprenorphine waivered physicians: the influence of state policies. J Subst Abuse Treat 2015;48:104-111.
33. Stein MD, Herman DS, Bailey GL, et al. Chronic pain and depressionamong primary care patients treated with buprenorphine. J Gen Intern Med 2015.
34. Streltzer J, Davidson R, Goebert D. An observational study of buprenorphine treatment of the prescription opioid dependent pain patient. Am J Addict 2015;24(4):357-361.
35. The Trustees of Dartmouth College. The Dartmouth atlas of health care [The Dartmouth Institute for Health Policy and Clinical Practice]. Available at: http://www.dartmouthatlas.org/. Accessed April 1, 2015.
36. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies: tackling the opioid-overdose epidemic. N Engl J Med 2014;370:2063-2066.
37. Walley AY, Alperen JK, Cheng DM, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med 2008;23:1393-1398.
38. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 2011;68:1238-1246.
39. West NA, Severtson SG, Green JL, Dart RC. Trends in abuse and misuse of prescription opioids among older adults. Drug Alcohol Depend 2015;149:117-121.